Mesenchymal Stem Cells Market Seen Reaching $15.42 Billion by 2035

Market Research Future projects the global mesenchymal stem cells market will grow from $5.48 billion in 2026 to $15.42 billion by 2035, powered by faster regulatory clearances, manufacturing scale-up and broader reimbursement. The report points to Ryoncil’s 2024 approval, bioreactor investments and expanding clinical adoption as key catalysts. Why it matters: - The market forecast points to a major shift in regenerative medicine as mesenchymal stem cell therapies move further from experimental use toward standardized care. - Faster approvals, larger manufacturing capacity and clearer reimbursement rules could make allogeneic MSC products more accessible in hospitals and specialty centers. - The projected rise to $15.42 billion by 2035 implies sustained demand across research, clinical and commercial cell therapy workflows. What happened: - Market Research Future said the global mesenchymal stem cells market is expected to reach $15.42 billion by 2035, up from $5.48 billion in 2026, at a 12.89% CAGR from 2026 to 2035. - The market base was estimated at $4.89 billion in 2025. - The forecast is tied to the 2024 regulatory clearance of Ryoncil, the first allogeneic mesenchymal stromal cell product approved in North America. - The report said at least four additional allogeneic MSC cell therapy applications are in rolling review across the U.S., Japan and Europe. - Request A Free Sample: Sample request The details: - Regulatory designations such as RMAT, SAKIGAKE and PRIME have compressed median review timelines by about 35%, according to agency data cited in the report. - Ryoncil’s 2024 approval came in under 18 months from BLA submission. - South Korea’s MFDS expanded its conditional approval framework in March 2025 to cover three new MSC-related indications, including degenerative disc disease and diabetic foot ulcers. - Bioreactor and closed-system manufacturing have pushed output above 10^10 cells per batch, compared with about 10^8 cells from traditional flask-based expansion. - The report said these systems cut labor costs by 50% to 60% and reduced batch-failure rates by up to 40%. - Contamination historically accounted for 12% to 15% of failures in open-system workflows. - Lonza and Cytiva have invested more than $800 million combined in dedicated cell therapy manufacturing suites since 2022. - Venture capital commitments to regenerative cell transplantation platforms exceeded $3.2 billion globally during 2023 and 2024. - CMS reimbursement codes for regenerative cell transplantation have supported adoption in academic medical centers, while community hospitals are increasingly using MSC therapies to manage chronic disease burden. - The report said product-specific HCPCS codes are expanding as payers respond to the first commercial allogeneic MSC treatment framework. - Read Detailed Insights: Full report Between the lines: - The strongest growth is coming from allogeneic products because they avoid patient-specific manufacturing and can be delivered faster than autologous therapies. - The report suggests the market is moving from a research-driven category to a commercial one, with reimbursement and manufacturing standardization becoming more important than pure clinical promise. - Hospitals and academic medical centers appear to be the early demand centers because they already have the infrastructure for cell processing, cryopreservation and specialized handling. - The forecast also signals that consumables, media and reagents remain a critical revenue engine, even as cell products gain attention. What’s next: - The report expects more allogeneic MSC approvals to move through rolling review in the U.S., Japan and Europe. - Patent expirations for key MSC manufacturing processes are expected in major markets between 2028 and 2030, which could lower regenerative cell transplantation costs by 20% to 25%. - By 2030, the report projects that 40% of newly approved cell therapy manufacturing facilities will use AI-driven potency prediction. - Machine-learning models trained on bone marrow stromal cell expansion data are expected to predict lot potency with more than 90% accuracy by 2028. - The report says release-testing timelines could fall from 14 days to under 72 hours. - Volume growth in Asia-Pacific and South America is expected to help offset pricing pressure from broader market entry. The bottom line: - Mesenchymal stem cells are moving into a phase defined by regulatory wins, scalable manufacturing and reimbursement access, with allogeneic products set to drive the next leg of growth.